Trump’s Take On COVID Testing Misses Public Health Realities
The president is arguing that the United States is finding more cases of COVID-19 because we are testing more.
Shefali Luthra
Was The Novel Coronavirus Really Sneaky In Its Spread To The U.S.? Experts Say No.
Unveiling a series of policies meant to mitigate the threat of COVID-19, President Donald Trump also sought to respond to criticism that his administration has been slow to deal with what is now a worldwide pandemic.
On Drug Pricing, The President’s Numbers Are Still Off
During the 2020 State of the Union address, President Donald Trump zeroed in on prescription drug prices, arguing that his administration is “taking on the big pharmaceutical companies.”
Sanders Targets Health Industry Profits. Are His Figures Right?
At the January Democratic debate, Vermont Sen. Bernie Sanders zeroed in on the question of profits in the health care industry.
Under “Medicare for All,” he said, “we end the $100 billion a year that the health care industry makes.”
Team Trump Says Administration’s Action On Health Care ‘Is Working.’ Is It?
With the 2020 election months away, President Donald Trump’s reelection campaign is touting his health care record as a key reason voters should grant him another term.
Do 160 Million Americans Really Like Their Health Plans? Kind Of
Articulating his proposal for health care reform, former Vice President Joe Biden emphasized the number of Americans who, he said, were more than perfectly satisfied with the coverage they have.
Surgeon General’s Marijuana Warning Omits Crucial Context
Speaking about a recent federal advisory on marijuana, Dr.
Trump’s Talk On Preexisting Conditions Doesn’t Match His Administration’s Actions
Delivering remarks on surprise medical billing, which is a concern that has drawn bipartisan interest, President Donald Trump waded into another high-profile health issue: making
Market Muscle: Study Uncovers Differences Between Medicare And Private Insurers
Private health insurance plans in 2017 paid more than twice what Medicare would have for those same health care services, says a sweeping new study from Rand Corp., a respected research organization.
Heart Drug Spotlights Troubling Trends In Drug Marketing
A company is marketing a drug intended as a preventive for people at risk for heart disease with stunning statistics but has not yet released details of its study.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.
Pages
